FY2017 Earnings Estimate for NeoGenomics, Inc. Issued By Gabelli (NEO)
NeoGenomics, Inc. (NASDAQ:NEO) – Analysts at Gabelli cut their FY2017 EPS estimates for NeoGenomics in a note issued to investors on Thursday. Gabelli analyst S. Wojda now anticipates that the medical research company will post earnings per share of $0.01 for the year, down from their previous forecast of $0.06. Gabelli currently has a “Buy” rating and a $9.00 target price on the stock. Gabelli also issued estimates for NeoGenomics’ FY2018 earnings at $0.16 EPS.
NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings results on Wednesday, October 25th. The medical research company reported $0.01 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.01. NeoGenomics had a positive return on equity of 3.97% and a negative net margin of 4.78%. The business had revenue of $63.05 million during the quarter, compared to the consensus estimate of $63.11 million. During the same quarter last year, the firm posted $0.04 EPS. The company’s quarterly revenue was up 3.8% on a year-over-year basis.
Shares of NeoGenomics (NEO) opened at $9.13 on Monday. NeoGenomics has a twelve month low of $7.12 and a twelve month high of $11.63. The stock has a market capitalization of $734.14, a price-to-earnings ratio of 182.60, a price-to-earnings-growth ratio of 8.70 and a beta of 0.85. The company has a current ratio of 2.14, a quick ratio of 1.99 and a debt-to-equity ratio of 0.57.
Institutional investors and hedge funds have recently bought and sold shares of the company. Wrapmanager Inc. acquired a new stake in shares of NeoGenomics during the second quarter worth $109,000. KCG Holdings Inc. acquired a new stake in shares of NeoGenomics during the first quarter worth $118,000. Empirical Finance LLC acquired a new stake in shares of NeoGenomics during the third quarter worth $159,000. Campbell & CO Investment Adviser LLC lifted its holdings in shares of NeoGenomics by 64.0% during the third quarter. Campbell & CO Investment Adviser LLC now owns 21,544 shares of the medical research company’s stock worth $240,000 after buying an additional 8,404 shares in the last quarter. Finally, OLD National Bancorp IN lifted its holdings in shares of NeoGenomics by 38.2% during the third quarter. OLD National Bancorp IN now owns 21,714 shares of the medical research company’s stock worth $242,000 after buying an additional 6,004 shares in the last quarter. 83.65% of the stock is owned by institutional investors.
NeoGenomics Company Profile
NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.
Receive News & Ratings for NeoGenomics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.